Macrophage migration inhibitory factor regulates interleukin-6 production by facilitating nuclear factor-kappa B activation during Vibrio vulnificus infection
- Chia-Chang Chuang†1, 2Email author,
- Yin-Ching Chuang3,
- Wen-Teng Chang4,
- Chi-Chung Chen3,
- Lien-I Hor6,
- A-Ming Huang5,
- Pui-Ching Choi1,
- Chi-Yun Wang1,
- Po-Chin Tseng1 and
- Chiou-Feng Lin†1, 6Email author
© Chuang et al; licensee BioMed Central Ltd. 2010
Received: 24 May 2010
Accepted: 12 October 2010
Published: 12 October 2010
Patients infected with Vibrio vulnificus (V. vulnificus) show severe inflammatory responses characterised by the upregulation of proinflammatory cytokines. Macrophage migration inhibitory factor (MIF), an upstream proinflammatory regulator, increases the inflammation caused by sepsis. Whether MIF regulates responses to V. vulnificus infection and the actual mechanism by which V. vulnificus initiates these MIF-modulated proinflammatory cytokines remain unclear.
MIF increased inflammation during V. vulnificus infection in vivo. In V. vulnificus-infected mice, MIF was produced earlier than tumour necrosis factor (TNF)-α and interleukin (IL)-6 and was expressed in a time-dependent manner. ISO-1 ((S, R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester), a small-molecule inhibitor of MIF, significantly decreased IL-6, IL-8, and TNF-α production in a time- and dose-dependent manner in human peripheral blood cells infected with V. vulnificus. The induction of IL-6, IL-8, and TNF-α production by V. vulnificus infection was mediated via the NF-κB- and p38 MAPK-regulated pathways but not via the Akt pathway. ISO-1-treated human peripheral blood cells showed lower V. vulnificus-induced NF-κB activation, IL-6 mRNA expression, and IκB phosphorylation, but they did not show lower p38 MAPK activation.
We conclude that MIF regulates V. vulnificus-induced IL-6 production via NF-κB activation and that p38 MAPK activation in V. vulnificus infection is not MIF dependent.
Vibrio vulnificus (V. vulnificus), a halophilic Gram-negative bacillus, causes a serious inflammatory process involving primary septicaemia and soft tissue infections . Patients with V. vulnificus infections have been reported in northern Europe, the United States, Australia, and Taiwan [2, 3]. In the U.S., approximately 50 confirmed cases of V. vulnificus are reported per year, most of which occur in the Gulf Coast region. The first case was reported in Taiwan in 1985, and the number of reported infections has increased because of greater disease activity or improved recognition by clinicians . Considerable data on the epidemiology of V. vulnificus has been obtained from Taiwan over the past two decades, and the involvement of environmental conditions, host factors, and bacterial virulence factors has led to a clearer understanding of the correlation between V. vulnificus infections and clinical manifestations. Numerous studies on V. vulnificus have investigated virulence factors, such as iron-overloading  and inflammation-associated cytokine production . V. vulnificus surface structures, such as lipopolysaccharide (LPS) and capsular polysaccharides, increase cytokine production [4, 5]. Further, overproduction and dysregulation of the host cytokine response to V. vulnificus, including tumour necrosis factor (TNF)-α, interleukin (IL)-6, and other inflammatory mediators, are critical in V. vulnificus-related endotoxaemic shock and lead to high mortality [6, 7]. However, the mechanisms of V. vulnificus-initiated signal transduction for these proinflammatory cytokines remain unclear.
Macrophage migration inhibitory factor (MIF), an important proinflammatory cytokine, is a critical mediator of innate immunity and is implicated in the pathogenesis of sepsis [8, 9]. Innate immune cells, including activated T cells, macrophages, and eosinophils, are the primary sites of MIF production after the host has been exposed to bacterial endotoxins and exotoxins. The released MIF modulates the expression of proinflammatory mediators, leading to early death in patients with sepsis [10–12]. In mice, the close linkage between MIF expression and Gram-negative and Gram-positive septic shock strongly suggests an intrinsic role for MIF in the innate immune response. Additionally, deleting the MIF gene or immunoneutralising MIF attenuates TNF-α production and protects against endotoxic shock [13, 14]. The molecular mechanism of MIF inhibition in decreasing deleterious cytokine activity during sepsis is currently under investigation. MIF-deficient macrophages are hypo-responsive to stimulation by LPS and Gram-negative bacteria because of a defect in Toll-like receptor 4 signalling and protein expression . These findings show that MIF is important in innate immunity and provide a rationale for the development of an anti-MIF strategy to treat patients with Gram-negative septic shock. The tautomerase active site of MIF has been proposed  as a potential target for MIF-modulating proinflammatory cytokines and might be used as a novel anti-inflammatory agent. Isoxazole acetic acid methyl ester (ISO-1), an inhibitor of MIF d-dopachrome tautomerase activity, has been shown to inhibit TNF-α secretion from LPS-treated macrophages and to protect mice from endotoxaemic . The importance of ISO-1-mediated inhibition of the MIF catalytic site in the suppression of cytokine proinflammatory activity suggests that the effect of ISO-1 requires endogenous MIF.
MIF binds to the CD74-CD44 complex and induces a signalling cascade that leads to activation of downstream signalling molecules, cellular proliferation, and inhibition of apoptosis by activating the Akt pathway through the upstream proteins Src and PI3K kinase [18, 19]. Nuclear factor-kappa B (NF-κB) and p38 mitogen-activated protein kinase (MAPK) are also critical intracellular signal transduction molecules involved in the pathogenesis of sepsis . NF-κB, a ubiquitous transcription factor, is responsible for the transcription of a diverse range of genes involved in sepsis and is a critical regulator of genes that encode TNF-α, IL-6, chemokines, and other inducible enzymes [21, 22]. As with NF-κB, p38 MAPK has been implicated as a critical mediator of the release of these proinflammatory cytokines during sepsis, and inhibiting p38 MAPK has an anti-inflammatory effect both in mice and in human endotoxaemic [20, 22]. It was recently reported  that MIF induced the expression of TNF-related apoptosis, inducing ligand and monocyte chemoattractant protein 1 in human diabetic podocytes, and that this MIF-induced expression is also p38 MAPK dependent. We investigated the effects of MIF and its molecular actions on proinflammatory cytokine production in V. vulnificus infection.
Bacterial strains and media
A clinical isolate of encapsulated V. vulnificus, Chi-Mei Vv05191, was obtained from the Chi-Mei Medical Center (Tainan, Taiwan) and was prepared as previously reported . A single colony was chosen and cultured at 35°C overnight in freshly prepared Mueller-Hinton broth. The bacterial suspension (400 μl) was then diluted 1:50 in Mueller-Hinton broth and incubated under the same conditions for 4 h. Bacteria were collected by centrifugation at 10,000 rpm for 10 min at 24°C. Pellets were resuspended and diluted to an inoculum with a final bacterial concentration of 1 × 107 colony-forming units (CFU)/ml (optical density: 0.22-0.25) before it was injected into mice or co-cultured with human whole blood or peripheral blood mononuclear cells (PBMCs). The inoculum concentration was confirmed by the subsequent growth of the concurrent culture on agar plates.
Inbred BALB/c female mice (age range: 4-5 weeks; mean weight: 20 g) were purchased from the Animal Center, National Science Council, Taipei, Taiwan. They were allowed to acclimatise for 5 to 7 days in the animal research laboratory of the Chi-Mei Medical Center. Food and water were supplied ad libitum. The experimental protocol adhered to the rules of the Animal Protection Act of Taiwan and was approved by the Laboratory Animal Care and Use Committee of the Chi-Mei Medical Center.
Preparing human cells
Buffy coats from healthy blood donors were obtained both from the Chi-Mei Medical Center and from the National Cheng Kung University Hospital. PBMCs were isolated by Ficoll-Hypaque gradient centrifugation (Pharmacia, Uppsala, Sweden) and prepared at a density of 2 × 106 cells/ml in RPMI. Blood was taken with informed consent from healthy volunteers in accordance with a protocol approved by the Human Experiment and Ethics Committees of both hospitals.
Measuring cytokine concentration
Infected mice were killed 3, 6, 9, and 12 h after they had been intraperitoneally inoculated with the Vv05191 strain of V. vulnificus. Serum samples obtained from the left axillary artery were stored at -80°C until they were assayed. In the infected human-cell model, the bacterial suspensions were added to whole blood or PBMCs at multiplicities of infection (MOI, ratio of bacteria to human PBMCs/whole blood cells) from 1 to 100. At designated times, plasma or supernatants were collected for analysis using enzyme-linked immunosorbent assays (ELISA). To determine the concentrations of cytokines, ELISA kits including MIF (Chemicon International, Temecula, CA, CYT264 for mouse and R&D Systems, Minneapolis, MN, DY289 for human), IL-6 (R&D, DY406 for mouse and R&D, DY206 for human), IL-8 (R&D, DY208 for human) and TNF-α (R&D, DY410 for mouse and R&D, DY210 for human), were used according to the manufacturer's instructions.
Inhibitors of MIF, p38 MAPK, NF-κB, and Akt
The MIF inhibitor (S, R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester (ISO-1) was obtained from Merck KGaA, (Darmstadt, Germany). Neutralising antibodies against human MIF and control goat IgG were purchased from R&D Systems. SB203580, pyrrolidine dithiocarbamate (PDTC), and LY294002 and wortmannin, selective inhibitors of p38 MAPK, NF-κB, and phosphoinositide 3-kinase/Akt, respectively, were purchased from Tocris Bioscience (Ellisville, MO). All drug treatments were assessed for cytotoxic effects using cytotoxicity and viability assays. Doses determined to be harmless were used.
We harvested the cells and lysed them with a buffer containing 1% Triton X-100, 50 mM Tris [pH 7.5], 10 mM ethylenediamine tetraacetic acid (EDTA), 0.02% NaN3, and a protease inhibitor cocktail (Roche Boehringer Mannheim Diagnostics, Mannheim, Germany). After they had been freeze-thawed once, the cell lysates were centrifuged at 9,000 × g at 4°C for 20 min. The supernatants were then collected and boiled in sample buffer for 5 min. After they were separated using SDS-PAGE, the proteins were transferred to polyvinylidene difluoride (PVDF) membranes (Millipore, Billerica, MA), blocked at 4°C overnight in PBS-T (PBS plus 0.05% Tween-20) containing 5% skim milk, and probed with primary antibodies at 4°C overnight. After they had been washed with PBS-T, the blots were incubated with a 1:5000 dilution of horseradish peroxide (HRP)-conjugated secondary antibody at 4°C for 1 h. The protein bands were visualised using enhanced chemiluminescence (ECL) (Pierce Biotechnology Inc., Rockford, IL), and the relative signal intensity was quantified using densitometry (LabWorks analysis software; UVP, LLC, Upland, CA). The extents of IκB, Akt, and p38 MAPK activation were determined using antibodies against phosphorylation (Cell Signaling Technology, Beverly, MA).
Electrophoretic mobility shift assays (EMSA)
Nuclear extracts from human PBMCs were prepared using a method, with minor modifications, described elsewhere . The cells were washed with 2 ml of phosphate-buffered saline (PBS) and resuspended in 1 ml of PBS. The cells were then centrifuged at 2,000 × g for 2 min, and the supernatant was discarded. The cell pellet was incubated in 300 μl of buffer A (10 mM HEPES [pH 7.9], 1.5 mM magnesium chloride, 10 mM potassium chloride, 0.5 mM phenylmethylsulfonyl fluoride, 0.5 mM dithiothreitol, 2 μg/ml leupeptin, 10 μg/ml aprotinin, 50 mM sodium fluoride, and 1 mM sodium orthovanadate) on ice for 10 min and then gently shaken for 10 s. The pellet of the crude nuclei was collected by centrifugation at 12,000 × g for 10 s, resuspended in 30 μl of buffer C (20 mM HEPES [pH 7.9], 25% glycerol, 420 mM sodium chloride, 1.5 mM magnesium chloride, 0.2 mM EDTA, 0.5 mM phenylmethylsulfonyl fluoride, 0.5 mM dithiothreitol, 2 μg/ml leupeptin, 10 μg/ml aprotinin, 50 mM sodium fluoride, and 1 mM sodium orthovanadate) using a vortexer for 15 s, and then incubated on ice for 20 min. After the cells had been centrifuged at 12,000 × g for 2 min, the supernatant containing the nuclear proteins was collected, quantified (BCA Protein Assay Reagent; Pierce), and stored in aliquots at -70°C. The EMSA used the following oligonucleotides as probes:
NF-κ B (f): 5'-CAA ATG TGG GAT TTT CCC ATG AGT;
NF-κ B (r): 5'-GAC TCA TGG GAA AAT CCC ACA TTT G.
The forward and reverse oligonucleotides (30 pmol) were placed in 23 μl of DNA polymerase buffer (Klenow 1×; Promega), heated at 94°C for 2 min, and then annealed at room temperature for 30 min. The annealed double-stranded oligonucleotides were end-labelled using a fill-in reaction with Klenow. One unit of the Klenow and 40 μCi of [α-32P] dCTP (PerkinElmer) were added to the annealed oligonucleotides, and then the mixture was incubated at 30°C for 15 min. The labelled oligonucleotides were purified using G-50 columns (Sephadex; PerkinElmer Life and Analytical Sciences, Inc., Boston, MA). The DNA binding reaction was done at 4°C for 30 min in a mixture containing 3 μg of nuclear extract, 10 mM Tris-Cl [pH 7.5], 50 mM sodium chloride, 0.5 mM dithiothreitol, 0.5 mM EDTA, 1 mM magnesium chloride, 4% glycerol, 0.05 μg of poly(dI-dC)-poly (dI-dC) (PerkinElmer), and 2 × 104 cpm of 32P-labelled double-stranded oligonucleotides. Samples were analysed on a 4% polyacrylamide gel (acrylamide/bis-acrylamide 29:1 in 0.5× Tris borate-EDTA buffer) at 10 V/cm for 2 h. The gel was dried and analysed using quantitative autoradiography computer densitometry.
Reverse-transcription polymerase chain reaction (RT-PCR)
The expression of mRNA was assessed using RT-PCR and quantified by real-time RT-PCR. Total cellular RNA was extracted from cells using TRIzol reagent (Invitrogen Corp., Carlsbad, CA) according to the manufacturer's instructions. RNA concentrations were quantified using a spectrophotometer (U-2000; Hitachi Koki Co., Ltd., Tokyo, Japan) at 260 nm. cDNA was prepared using reverse transcription, and PCR was done using a thermal cycler (GeneAmp PCR system 2400; PerkinElmer). Based on published sequences and sequences that we designed with Primer 3 online software http://frodo.wi.mit.edu/primer3/, we used the following oligonucleotide primers:
β-actin: sense, 5'-TGG AAT CCT GTG GCA TCC ATG AAA C-3' and
antisense, 5'-TAA AAC GCA GCT CAG TAA CAG TCC G-3';
IL-6: sense, 5'-ATG AAC TCC TTC TCC ACA AGC GC-3' and
antisense, 5'-GAA GAG CCC TCA GGC TGG ACT G-3'.
The PCR products were analysed with 1.5% agarose gel electrophoresis, stained with ethidium bromide, and then viewed with ultraviolet (UV) light using a gel camera (UVP) . The levels of IL-6 mRNA were also quantified using Gene Expression Assays and 2× master mix on a StepOne Real-Time PCR system (Applied Biosystems, California, USA). Cellular RNA was extracted as described for RT-PCR and the oligonucleotide primers were as follows:
β-actin: sense, 5'-CTG GAC TTC GAG CAA GAG ATG-3' and
antisense, 5'-TGA TGG AGT TGA AGG TAG TTT CG-3';
IL-6: sense, 5'-TAC CCC CAG GAG AAG ATT CC-3' and
antisense, 5'-CAG TGC CTC TTT GCT GCT TTC-3'.
Student's t test was used to analyse the data (SigmaPlot 8.0 for Windows; Systat Software, Inc., San Jose, CA). All data are represented by the means ± SD of at least three individual experiments. P < 0.05 was considered statistically significant.
MIF was expressed before IL-6 and TNF-α in V. vulnificus-infected mice
MIF was an upstream modulator of IL-6, IL-8, and TNF-α
NF-κB and p38 MAPK signalling were essential for IL-6, IL-8, and TNF-α production
MIF facilitated NF-κB activation
NF-κB was essential for the transcriptional activation of MIF-induced IL-6 expression
Because NF-κB is an important transcription factor for IL-6 expression and binds to its response element on the IL-6 promoter [20, 21, 27], we examined whether increased NF-κB binding activity upregulates IL-6 in V. vulnificus-infected human PBMCs. We used EMSA with probes containing the putative NF-κB binding site on the IL-6 promoter to measure NF-κB binding activity. After the PBMCs had been infected with V. vulnificus, NF-κB binding was higher in control cells than in PBMCs treated with ISO-1 (Figure 4C, lanes 2, 3). RT-PCR and real-time RT-PCR showed that IL-6 mRNA levels were lower in V. vulnificus-infected PBMCs treated with ISO-1 than in those not treated with ISO-1 (Figure 4D). Taken together, these results suggest that MIF is crucial upregulator of IL-6 at the transcription level in V. vulnificus-infected cells and that this upregulation is the result of NF-κB activation.
In this study, we showed that MIF regulated the production of TNF-α, IL-6, and IL-8 in V. vulnificus-infected human PBMCs, which is consistent with the findings of other studies [8, 9]. High serum levels of IL-6, a crucial immunoregulator in patients with early-phase Gram-negative sepsis, predict poor outcomes for patients with sepsis [28, 29]. IL-6 increases at early time points in patients with severe sepsis and septic shock [12, 30]. IL-8 also is induced in human intestinal epithelial cells infected with V. vulnificus, and IL-8 mRNA expression increases as the result of NF-κB activation . In the present study, we provide evidence that MIF upregulates IL-6, IL-8, and TNF-α in cells infected with V. vulnificus. We hypothesise that MIF is an initial proinflammatory mediator during V. vulnificus infection, which is consistent with previous reports [12, 14] on patients with sepsis and endotoxaemic models.
We showed that V. vulnificus infection significantly increased IL-6 mRNA expression and NF-κB binding in human PBMCs. We also showed that V. vulnificus infection increased IL-6 gene expression via NF-κB activation in human PBMCs and that ISO-1, a small molecule inhibitor of MIF, downregulated the transcription of IL-6 and NF-κB activation. While ISO-1 has a different effect on Toll-like receptor 4-induced inflammatory responses , our findings indicate that IL-6 gene expression is regulated by MIF activation of NF-κB. Although V. vulnificus infection induced MIF-regulated proinflammatory cytokines, only high-dose treatments of ISO-1 inhibited TNF-α production, which indicated that an MIF-independent signalling pathway might exist for regulating TNF-α during V. vulnificus infection.
In the present study, we found that the p38 MAPK and NF-κB pathways were the major signalling pathways through which cytokine release was induced in human PBMCs infected with V. vulnificus. Furthermore, a recent study  reported that p38 MAPK was essential for group B streptococcus-induced MyD88-dependent induction of TNF-α production but was unnecessary for NF-κB activation . However, based on our findings, it appears that V. vulnificus-induced IL-6 production is facilitated by MIF via NF-κB activation but not by p38 MAPK. The different responses and their molecular mechanisms need further investigation.
Inhibiting MIF with ISO-1 downregulated the phosphorylation of IκB and partially inhibited NF-κB binding activity and the mRNA expression of IL-6, which suggested that MIF is an important upregulator of IL-6 production via NF-κB activation. Although the ISO-1-mediated downregulation of NF-κB binding and IL-6 mRNA expression was less significant than the downregulation of IL-6 production, the discrepancy between the upregulation of transcription and protein production suggests that these processes are controlled by different mechanisms. In our preliminary studies, we found a significant decrease in protein production after ISO-1 treatment in both the intracellular and extracellular phases. However, the mechanism that ISO-1 uses to inhibit intracellular protein production is unknown.
We have shown that MIF significantly upregulated IL-6 production by facilitating NF-κB activation in human PBMCs infected with V. vulnificus. These data may help in the development of strategies to target MIF with specific inhibitors or neutralising antibodies when treating V. vulnificus infection.
List of abbreviations
isoxazole acetic acid methyl ester
macrophage migration inhibitory factor
tumour necrosis factor alpha
nuclear factor-kappa B
mitogen-activated protein kinase
multiplicity of infection
peripheral blood mononuclear cells
sodium dodecyl sulphate polyacrylamide gel electrophoresis
enzyme-linked immunosorbent assay
electrophoretic mobility shift assay
reverse transcription-polymerase chain reaction
This work was supported in part by grants NCKUH-9701016 (to CCC and LIH) from the National Cheng Kung University Hospital Research Council, the Institute of Clinical Medicine, and CMFHR-9754 (to YCC), from the Chi-Mei Medical Center. The authors declare that they have no financial conflicts of interest.
- Tsuchiya T, Mitsuo E, Hayashi N, Hikita Y, Nakao H, Yamamoto S, Miyamoto K, Tsujibo H: Vibrio vulnificus damages macrophage during the early phase of infection. Infect Immun. 2007, 75: 4592-4596. 10.1128/IAI.00481-07.PubMed CentralView ArticlePubMedGoogle Scholar
- Strom MS, Paranjpye RN: Epidemiology and pathogenesis of Vibrio vulnificus. Microbes Infect. 2000, 2: 177-188. 10.1016/S1286-4579(00)00270-7.View ArticlePubMedGoogle Scholar
- Hsueh PR, Lin CY, Tang HJ, Lee HC, Liu JW, Liu YC, Chuang YC: Vibrio vulnificus in Taiwan. Emerg Infect Dis. 2004, 10: 1363-1368.PubMed CentralView ArticlePubMedGoogle Scholar
- Hor LI, Chang YK, Chang CC, Lei HY, Ou JT: Mechanism of high susceptibility of iron-overloaded mouse to Vibrio vulnificus infection. Microbiol Immunol. 2000, 44: 871-878.View ArticlePubMedGoogle Scholar
- Powell JL, Wright AC, Wasserman SS, Hone DM, Morris JG: Release of tumor necrosis factor alpha in response to Vibrio vulnificus capsular polysaccharide in in vivo and in vitro models. Infect Immun. 1997, 65: 3713-3718.PubMed CentralPubMedGoogle Scholar
- Shin SH, Shin DH, Ryu PY, Chung SS, Rhee JH: Proinflammatory cytokine profile in Vibrio vulnificus septicemic patients' sera. FEMS Immunol Med Microbiol. 2002, 33: 133-138. 10.1111/j.1574-695X.2002.tb00582.x.View ArticlePubMedGoogle Scholar
- Chiang SR, Tang HJ, Chang PC, Cheng KC, Ko WC, Chen CH, Chuang YC: Synergistic antimicrobial effect of cefotaxime and minocycline on proinflammatory cytokine levels in a murine model of Vibrio vulnificus infection. J Microbiol Immunol Infect. 2007, 40: 123-133.PubMedGoogle Scholar
- Baugh JA, Bucala R: Macrophage migration inhibitory factor. Crit Care Med. 2002, 30: S27-S35. 10.1097/00003246-200201001-00004.View ArticleGoogle Scholar
- Lue H, Kleemann R, Calandra T, Roger T, Bernhagen J: Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Microbes Infect. 2002, 4: 449-460. 10.1016/S1286-4579(02)01560-5.View ArticlePubMedGoogle Scholar
- Mitchell RA, Liao H, Chesney J, Fingerle-Rowson G, Baugh J, David J, Bucala R: Macrophage migration inhibitory factor sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci USA. 2002, 99: 345-350. 10.1073/pnas.012511599.PubMed CentralView ArticlePubMedGoogle Scholar
- Emonts M, Sweep FCGJ, Grebenchtchikov N, Geurts-Moespot A, Knaup M, Chanson AL, Erard V, Renner P, Hermans PWM, Hazelzet JA, Calandra T: Association between high levels of blood macrophage migration inhibitory factor, inappropriate adrenal response, and early death in patients with severe sepsis. Clin Infect Dis. 2007, 44: 1321-1328. 10.1086/514344.View ArticlePubMedGoogle Scholar
- Chuang CC, Wang ST, Chen WC, Chen CC, Hor LI, Chuang YC: Increases in serum macrophage migration inhibitory factor in patients with severe sepsis predict early mortality. Shock. 2007, 27: 503-506. 10.1097/SHK.0b013e31802c024b.View ArticlePubMedGoogle Scholar
- Bozza M, Satoskar AR, Lin G, Lu B, Humbles AA, Gerard C, David JR: Targeted disruption of macrophage migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med. 1999, 189: 341-346. 10.1084/jem.189.2.341.PubMed CentralView ArticlePubMedGoogle Scholar
- Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, Hultner L, Heumann D, Mannel D, Bucala R, Glauser MP: Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med. 2000, 6: 64-170. 10.1038/72262.View ArticleGoogle Scholar
- Roger T, Froidevaux C, Martin C, Calandra T: Macrophage migration inhibitory factor (MIF) regulates host responses to endotoxin through modulation of Toll-like receptor 4 (TLR4). J Endotoxin Res. 2003, 9: 119-123.View ArticlePubMedGoogle Scholar
- Lubetsky JB, Dios A, Han J, Aljabari B, Ruzsicska B, Mitchell R, Lolis E, Al-Abed Y: The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J Biol Chem. 2002, 277: 24976-24982. 10.1074/jbc.M203220200.View ArticlePubMedGoogle Scholar
- Al-Abed Y, Dabideen D, Aljabari B, Valster A, Messmer D, Ochani M, Tanovic M, Ochani K, Bacher M, Nicoletti F, Metz C, Pavlov VA, Miller EJ, Tracey KJ: ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J Biol Chem. 2005, 280: 36541-36544. 10.1074/jbc.C500243200.View ArticlePubMedGoogle Scholar
- Gore Y, Starlets D, Maharshak N, Becker-Herman S, Kaneyuki U, Leng L, Bucala R, Shachar I: Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. J Biol Chem. 2008, 283: 2784-27892. 10.1074/jbc.M703265200.View ArticlePubMedGoogle Scholar
- Lue H, Thiele M, Franz J, Dahl E, Speckgens S, Leng L, Fingerle-Rowson G, Bucala R, Luscher B, Bernhagen J: Macrophage migration inhibitory factor promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene. 2007, 26: 5046-5059. 10.1038/sj.onc.1210318.View ArticlePubMedGoogle Scholar
- O'Sullivan AW, Wang JH, Redmond HP: NF-κB and p38 MAPK inhibition improve survival in endotoxic shock and in a cecal ligation and puncture model of sepsis in combination with antibiotic therapy. J Surg Res. 2009, 152: 46-53. 10.1016/j.jss.2008.04.030.View ArticlePubMedGoogle Scholar
- Liu SF, Malik AB: NF-κB activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol. 2006, 290: L622-L645. 10.1152/ajplung.00477.2005.View ArticlePubMedGoogle Scholar
- Branger J, van den Blink B, Weijer S, Madwed J, Bos CL, Gupta A, Yong CL, Polmar SH, Olszyna DP, Hack CE, van Deventer SJH, Peppelenbosch MP, van der Poll T: Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J Immunol. 2002, 168: 4070-4077.View ArticlePubMedGoogle Scholar
- Sanchez-Nino MD, Sanz AB, Ihalmo P, Lassila M, Holthofer H, Mezzano S, Aros C, Groop PH, Saleem MA, Mathieson PW, Langham R, Kretzler M, Nair V, Lemley KV, Nelson RG, Mervaala E, Mattinzoli D, Rastaldi MP, Ruiz-Ortega M, Martin-Ventura JL, Egido J, Ortiz A: The MIF receptor CD74 in diabetic podocyte injury. J Am Soc Nephrol. 2009, 20: 353-362. 10.1681/ASN.2008020194.PubMed CentralView ArticlePubMedGoogle Scholar
- Chang WT, Huang AM: Pal/NRF-1 regulates the promoter of the human Integrin-associated protein/CD47 Gene. J Biol Chem. 2004, 279: 14542-14550. 10.1074/jbc.M309825200.View ArticlePubMedGoogle Scholar
- Tsai CC, Kai JI, Huang WC, Wang CY, Wang Y, Chen CL, Fang YT, Lin YS, Anderson R, Chen SH, Tsao CW, Lin CF: Glycogen synthase kinase-3β facilitates IFN-γ-induced STAT1 activation by regulating Src homology-2 domain-containing phosphatase 2. J Immunol. 2009, 183: 856-864. 10.4049/jimmunol.0804033.View ArticlePubMedGoogle Scholar
- Kenzel S, Santos-Sierra S, Deshmukh SD, Moeller I, Ergin B, Fitzgerald KA, Lien E, Akira S, Golenbock DT, Henneke P: Role of p38 and early growth response factor 1 in the macrophage response to group B streptococcus. Infect Immun. 2009, 77: 2474-2481. 10.1128/IAI.01343-08.PubMed CentralView ArticlePubMedGoogle Scholar
- Matsui H, Ihara Y, Fujio Y, Kunisada K, Akira S, Kishimoto T, Yamauchi-Takihara K: Induction of interleukin (IL)-6 by hypoxia is mediated by nuclear factor (NF)-κB and NF-IL6 in cardiac myocytes. Cardiovasc Res. 1999, 42: 104-112. 10.1016/S0008-6363(98)00285-5.View ArticlePubMedGoogle Scholar
- Calandra T, Gerain J, Heumann D, Baumgartner JD, Glauser MP: High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group. Am J Med. 1991, 91: 23-29. 10.1016/0002-9343(91)90069-A.View ArticlePubMedGoogle Scholar
- Damas P, Ledoux D, Nys M, Vrindts Y, De Groote D, Franchimont P, Lamy M: Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg. 1992, 215: 356-362. 10.1097/00000658-199204000-00009.PubMed CentralView ArticlePubMedGoogle Scholar
- Bozza FA, Gomes R, Japiassú AM, Soares M, Castro-Faria-Neto HC, Bozza PT, Bozza MT: Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock. 2004, 22: 309-313. 10.1097/01.shk.0000140305.01641.c8.View ArticlePubMedGoogle Scholar
- Lee BC, Kim SH, Choi SH, Kim TS: Induction of interleukin-8 production via nuclear factor-κB activation in human intestinal epithelial cells infected with Vibrio vulnificus. Immunology. 2005, 115: 506-515. 10.1111/j.1365-2567.2005.02185.x.PubMed CentralView ArticlePubMedGoogle Scholar
- West PW, Parker LC, Ward JR, Sabroe I: Differential and cell-type specific regulation of responses to Toll-like receptor agonists by ISO-1. Immunology. 2008, 125: 101-110. 10.1111/j.1365-2567.2008.02825.x.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.